The UA is the lead institution for the Regional Algal Feedstock Testbed, or RAFT, partnership, which was recently awarded $8 million over four years by the Department of Energy to research how algae can be grown year-round outdoors in open ponds in different climates.Continue reading
Category Archives: Health
Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers
Exclusive license agreement paves the way for industry’s first BRAF V600E IHC testContinue reading
TGen-led study identifies genes associated with unhealthy liver function
Study with Geisinger Health System tests nearly 2,300 extremely obese diabetes patientsContinue reading
UACC study works to improve breast cancer treatment by combining nutrition and medicine
TUCSON, Ariz. – University of Arizona Cancer Center researchers are seeking participants in Maricopa County for a study designed to determine if a compound found in broccoli can enhance the health-promoting effects of the breast cancer drug Tamoxifen in women at risk of developing breast cancer or those previously treated for early-stage breast cancer.Continue reading
PROOF Partners with HTG Molecular on Heart Transplant Rejection Blood Test
The PROOF Centre of Excellence Partners with HTG Molecular Diagnostics to Begin Clinical Validation of Heart Transplant Rejection Blood TestContinue reading
It’s Life in the Fast Lane for Iron Horse Dx
Iron Horse Diagnostics to receive the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association for Accelerating the Development of New ALS Diagnostic Tests.
Amyotrophic Lateral Sclerosis (also known as ALS or Lou Gehrig’s disease) is a devastating disease that is nearly always fatal within 5 years of onset. Due to similarities in their symptomatic progression is it difficult to differentiate ALS from several other disease mimics (motor neuropathy, progressive muscle atrophy, etc.) until it is too late for intervention to have any real effect. With an earlier diagnosis, and therefore earlier intervention, current clinical care may increase the lifespan of these patients and additional drug therapies that are likely to be introduced to the market could be more rapidly initiated. Not only might life expectancy increase, but patients would be given the chance for a higher quality of life for a longer duration due to more rapid inclusion of the patient into multi-disciplinary care treatment offered at specialized ALS clinics.Continue reading
MSDx Announces Issuance of First Patent for Monitoring Disease Activity in a Multiple Sclerosis Patient
TUCSON, AZ, September 17, 2013 – MSDx, Inc., a personalized medicine diagnostics company developing blood test products for monitoring disease activity in neurological disorders, announced today that the United States Patent and Trademark Office issued a patent that broadly protects the company’s exclusive rights for monitoring or detecting Multiple Sclerosis (MS) in a patient, utilizing its proprietary technology.Continue reading
Nasseo’s TiArray™ Dental Implant System Receives FDA Approval
Nasseo, Inc. announced today that the FDA has approved its TiArray™ Dental Implant System for commercial sale in the U.S. It was developed to address a gap in medical care that is currently adding significant costs to the US healthcare system: the failure of dental implants.Continue reading
Leslie Boyer, M.D. Named Arizona Bioscience Researcher of the Year
Dr. Leslie Boyer, founding director of the VIPER (Venom Immunochemistry, Pharmacology and Emergency Response) Institute at the University of Arizona College of Medicine to receive the 2013 Arizona Bioscience Researcher of the Year Award.Continue reading